Promoter holding
64.27%
GP
Galentic Pharma India Pvt Ltd - Due diligence report
A 360° intelligence report on Galentic Pharma India Pvt Ltd: trust score, financial health, credit view, compliance, directors, growth and d…
Full Due-Diligence Report + Documents
- Unlock all financial figures & 5-year trends
- Full trust, health & credit-risk scores
- Director details, charges & MCA documents
₹700
₹449
Save ₹251
excl. GST
Or from ₹279/report with credits
View credit packages
Company Credits – Starter
- One credit unlocks this full due-diligence report
- Use across any company’s report, anytime
- Credits valid for 12 months
Choose your own credit amount
View credit packages
Galentic Pharma India Pvt Ltd — 360° Intelligence Report
Generated from MCA filings & public records84/100
Trust Score
Low Risk
Galentic Pharma India Pvt Ltd is assessed as Low Risk with a Trust Score of 84/100. Galentic Pharma India Pvt Ltd is an active private limited indian non-government company incorporated in 1992, operating in the Pharma sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and low financial risk profile.
Report generated on 17 Jul 2026 from the latest processed filings. Galentic Pharma India Pvt Ltd snapshot & full profile →
Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.
02
Score Card
Higher is safer · rule-based & explainableTrust ScoreLow Risk
84/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
75/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
85/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreLow Risk
95/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreModerate
65/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
75/100
Early-warning signals - higher means fewer warnings.
03
Financial Intelligence Dashboard
Standalone · 5 filed year(s)Unlock the full 5-year financial dashboard with charts and year-wise figures.
Get full accessScores and observations on this page are already computed from the real filings - only the underlying figures are locked.
04
Credit & Compliance Intelligence
Why the scores are what they are
Credit Risk Score: 95/100 Low Risk
- Liabilities ≈ 38% EBITDA - serviceable.
- Moderate gearing (D/E 1.42).
- Working-capital cover adequate.
- Profitable - internal accruals available.
Charges position: 7 open (131.07 cr) · 1 satisfied (1.27 cr).
Banking relationships (from registered charges)
| Lender | Charges | Amount |
|---|---|---|
| Hdfc Bank Limited | 5 | 48.0 cr |
| Citi Bank N.A. | 2 | 48.0 cr |
| The South Indian Bank Ltd. | 1 | 48.0 cr |
Compliance Score: 75/100 Low Risk
- Company status is Active as per MCA.
- Annual filings current (balance sheet Mar 2025).
- Litigation present in 1 court forum(s).
- 1 auditor resignation(s) filed - latest: Kiran Desai & Associates on 2022-02-15.
- Delayed payments to MSME suppliers disclosed (1 disclosure(s)).
- 3 active GST registration(s).
Legal cases on record (1)
05
Director Intelligence
Stability score: 95/100| Name | DIN / PAN | Designation | Appointed | Tenure | DIN status |
|---|---|---|---|---|---|
| SMITA BHUPENDRA SANGANI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| AMISHA MAULIN GANDHI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| BHUPENDRA HARKISANDAS SANGANI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| MANTHAN KAMLESH VOHRA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| JAY NARENDRA MEHTA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| HEMANG KAMLESH VOHRA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| KAMLESH SATYENDRA VOHRA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
- 7 directors on the board.
- No disqualified or deactivated DINs.
- Stable board - no exits in 3 years.
- Average tenure above 5 years.
Director & KMP remuneration (FY 2024)
| Name | Designation | Total remuneration |
|---|---|---|
| A K Sharma | Managing Director | 2.4 cr |
| R Mehta | Whole-time Director | 1.6 cr |
| S Iyer | CFO | 95.0 L |
Remuneration is disclosed in the latest annual return. Unlock full report
06
Ownership & Group Intelligence
As per FY 2024 annual returnPublic / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
1
Group entities
1
Capital events
1 allotment(s) · 7 transfer(s)
Promoters hold a majority stake - exact percentages are part of the full report.
| Group entity | Relationship | % held |
|---|---|---|
| The Ethical Pharmaceutical Co. Private Limited | Subsidiary Company | 74.00% |
Key managerial personnel: BHUPENDRA HARKISANDAS SANGANI (Managing Director)
Full shareholding pattern, group structure & capital events →
07
Risk Intelligence Center
Growth 65 · Distress 75
Growth signals & trust indicators
Steady revenue growth: +2.1x over 4 year(s).
EPFO headcount growing - hiring signal.
Operating for 34+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Revenue declined year-on-year.
7 open charge(s) registered - assets are encumbered.
1 auditor resignation(s) on record - review the stated reasons.
MSME payment delays disclosed - latest outstanding 12.52 Lakh.
1 court case(s) on record - see the legal section for details.
08
Stakeholder Verdicts
Vendor · Banker · InvestorVendor due diligence78/100
Favourable indicators
Suitability as a supplier / customer counterparty.
- Statutory record is clean.
- 1 distress signal(s) - see Risk Center.
- Financial filings available for verification.
Banker assessment87/100
Favourable lending indicators
Indicative lending comfort for banks, NBFCs and trade credit.
- Debt capacity assessed from filed statements.
- 7 open charge(s) of 131.07 cr already registered.
- Compliance record supports lending.
Investor view77/100
Positive growth indicators
Growth quality and scalability through an investor lens.
- 2 growth signal(s) detected.
- Margin and return trends computable from filings.
- Management team looks stable.
09
MCA Filings & Events Timeline
Latest 15 events30 Sep 2025
Last AGM held
Annual general meeting
28 Apr 2025
Charge created
Hdfc Bank Limited - 32.40 Lakh
31 Mar 2025
Latest balance sheet
Filed with ROC
30 Sep 2022
Director ceased
JAY NARENDRA MEHTA
31 Mar 2022
Share transfer (FY 2022)
100.00000000 shares to HEMANG KAMLESH VOHRA
Share transfer (FY 2022)
100.00000000 shares to JAY NARENDRA MEHTA
25 Feb 2022
Charge created
Citi Bank N.A. - 7.20 cr
21 Jan 2022
Charge created
Citi Bank N.A. - 15.00 cr
28 Sep 2021
Director appointed
AMISHA MAULIN GANDHI (Director)
Director appointed
MANTHAN KAMLESH VOHRA (Director)
Director appointed
JAY NARENDRA MEHTA (Director)
22 Sep 2021
Director ceased
AMISHA MAULIN GANDHI
Director ceased
MANTHAN KAMLESH VOHRA
31 Mar 2021
Share transfer (FY 2021)
133.00000000 shares to ELLA PARIMAL PARIKH
Share transfer (FY 2021)
67.00000000 shares to BHUPENDRA HARKISANDAS SANGANI
10
Key Observations
Auto-generated from the data aboveRevenue grew 24% over the last 4 financial year(s).
Net profit margin moved from 0.86 to 61%.
Debt-to-equity stands at 38% - manageable leverage.
Net worth is positive.
Compliance record is strong - status, filings and flags are clean.
7 active director(s) / partner(s); board looks stable and experienced.
3 active GST registration(s) indicate ongoing business operations.
Operates a group structure with 1 subsidiary(ies) - assess on a consolidated basis.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a majority stake as per the FY 2024 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 1 security allotment(s) - amounts available in the full report.
| Company | CIN | Location |
|---|---|---|
| Crystic Resins | U74899DL1971PTC003578 | Delhi, Delhi, India |
| Super Formulations Private Limited | U24232MP2004PTC016782 | Ujjain, Madhya Pradesh, India |
| Yeluri | U24230TG1997PTC026188 | Hyderabad, Telangana, India |
| Navdeep Chemicals | U24100MH1978PTC020113 | Mumbai, Maharashtra, India |
| Jagson Colorchem Limited | U24231GJ1996PLC030010 | Ahmedabad, Gujarat, India |
| Aglowmed Limited | U24232BR1983PLC001901 | Patna, Bihar, India |
| Shine Pharmaceuticals | U24231GJ1994PLC022787 | Vadodara, Gujarat, India |
| Gujarat Multi Gas Base Chemicals Private Limited | U24231GJ1989PTC011795 | Mensana, Gujarat, India |
12
Who Uses This Report
CA · CS · Banker · Investor · VendorChartered Accountants (CA)
Verify Galentic Pharma India Pvt Ltd before audits and certifications: compliance score 75/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.
Company Secretaries (CS)
Track statutory health of Galentic Pharma India Pvt Ltd: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.
Bankers & NBFCs
Current banker verdict: Favourable lending indicators. Credit risk score 95/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.
Investors & Analysts
Investor view: Positive growth indicators. Growth score 65/100, margin trends, ownership structure and peer set for Galentic Pharma India Pvt Ltd - screening before a deeper diligence.
Vendors & Procurement Teams
Vendor verdict: Favourable indicators. Trust score 84/100, distress signals and MSME payment-delay disclosures - know whether Galentic Pharma India Pvt Ltd pays its suppliers before you extend credit terms.
Lawyers & Compliance Teams
Litigation footprint (1 case(s) on record), regulatory flags, charge documents trail and director networks for Galentic Pharma India Pvt Ltd - groundwork for KYC, onboarding and disputes.
13
Frequently Asked Questions
Is Galentic Pharma India Pvt Ltd an active company?
Galentic Pharma India Pvt Ltd has MCA status “Active” with a compliance score of 75/100 (Low Risk).
Is Galentic Pharma India Pvt Ltd financially healthy?
Galentic Pharma India Pvt Ltd has a Financial Health Score of 85/100 (Low Risk) based on its filed financial statements.
Should I do business with Galentic Pharma India Pvt Ltd?
Its overall Trust Score is 84/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.
Who controls Galentic Pharma India Pvt Ltd?
Promoters hold a majority stake - exact percentages are in the full report. 7 active director(s) are on record.
Does Galentic Pharma India Pvt Ltd have loans or charges against its assets?
7 open charge(s) are registered against its assets, and 1 earlier charge(s) stand satisfied.
Is Galentic Pharma India Pvt Ltd up to date with its ROC filings?
Annual filings current (balance sheet Mar 2025). Overall compliance score: 75/100 (Low Risk).
Is it risky to lend to Galentic Pharma India Pvt Ltd?
Its Credit Risk Score is 95/100 (Low Risk). Banker verdict: Favourable lending indicators.
Disclaimer: This report is generated automatically from MCA filings and public records as available
in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the
underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are
not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice.
Verify from official sources and consult a qualified professional before any business, lending or investment decision.
If you represent this company and believe any information is inaccurate or outdated,
report it here and we will review promptly.
